

FOR IMMEDIATE RELEASE

Virutase™ Selected to Treat African Children

Accra, Ghana, West Africa (1 August 2004) – Virutase™, a new family of anti-viral treatments, is going to Africa. The Serendipity (Ghana) Foundation, in conjunction with the Serendipity International Foundation, has selected Virutase™ for treating African children suffering from viral illnesses. In addition, the new treatment will be made available to clinics in Ghana for ongoing testing with HIV and AIDS patients.

“We’ve already sent 5,000 doses over for HIV and AIDS testing,” says Harley Phillips, Chairman of Serendipity International Foundation, “and now we’re sending another 8,000 doses specifically for treating children with various viral illnesses. The earlier testing for HIV, AIDS, Influenza and other viruses has seen remarkable results so this shipment will provide more Virutase™ for both continued research as well as for direct treatment.”

“Influenza is rampant in western Africa and many thousands die from it each year.” according to Godwin Fiadjoe, head of the Serendipity (Ghana) Foundation in Accra, “Children are particularly susceptible and Virutase™ can give their families real hope.” There are other viral illnesses including hepatitis, polio and many others causing suffering in western Africa. However, the initial human testing of Virutase™ showed it to be particularly effective against influenza, herpes and Epstein-Barr. Therefore, the primary treatment efforts will focus on those diseases for now.

At the same time, several clinics in Accra are testing Virutase™ for treating and helping strengthen the immune systems of HIV and AIDS patients. The first results have been very encouraging and two clinics have asked for immediate supplies to continue testing. The government of Ghana has already given preliminary approval for using Virutase™ in Ghana and full certification will be completed by this fall. Many other countries in Africa are watching Ghana closely and once this certification is complete, they have already expressed their intention to provide Virutase™ to their patients as well.

With successful testing of Virutase™ as a treatment for HIV and AIDS, the benefits to the U.S., Canada and the rest of the western world could be enormous. The cost is low, the raw materials plentiful and the patented process already set up for large scale manufacturing. Virutase™ could be one of the most significant new products for treating viral illness ever discovered.

Developed originally as a potential treatment for hepatitis, Virutase™ has shown a remarkable ability to inhibit viral attachment to healthy blood cells which allows the immune system to strengthen and the body to heal itself faster. Virutase™ is manufactured by PBS, LLC of Las Vegas, Nevada, a small private company dedicated to bringing it to market worldwide. The Serendipity International Foundation is a 501c3 public charity dedicated to helping children and families in Africa. Please visit their website and offer your support.

The website for the Serendipity Foundation is:

<http://www.serendipityfoundation.org> – Email: [info@serendipityfoundation.org](mailto:info@serendipityfoundation.org)

You can see more about Virutase™ at their website:

<http://www.Virutase.com> – email: [info@Virutase.com](mailto:info@Virutase.com)

Interview Contact:        Robert B. Sommer at 760-945-4415 (PBS, LLC)  
                                     Harley Phillips at 760-803-9222 (Serendipity International Foundation)

PBS, LLC  
2588 El Camino Real, F267, Carlsbad, California 92008  
760-945-4415  
760-729-0744 FAX

###